The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 1,000
Zeyfang, A., Gölz, S., Iraci, F., Wagner, C., Scheer, C., Kubiak, T., Bozkurt, L., Heni, M., & Holl, R. W. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105724 · Cited by 3
Which Patients with Heart Failure Benefit from an SGLT2 Inhibitor?
Benjamen, J., & Fralick, M. (2025) · NEJM Evidence · doi:10.1056/evidccon2400446 · Cited by 3
Rosenthal, L., Miera, O., Krauß, A., Danne, F., Berger, F. F., & Kramer, P. P. G. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15386 · Cited by 3
Левонович, Ч. А., Tunyan, L. G., Arzumanyan, М. А., & Balyan, H. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00053-6 · Cited by 3
Elmegaard, M., Køber, L., Ersbøll, M. K., Lange, T., Tuxen, C., Mouridsen, M. R., Lauridsen, T. K., Thune, J. J., Jørgensen, P. G., Lamberts, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15398 · Cited by 3
Self-citationIssa, R., Calcagno, T., Canova, T., Issa, R., Kaelber, D. C., Menon, V., Tang, W. H. W., Griffin, B. P., Kwon, D. H., & Wang, T. K. M. (2025) · Angiology · doi:10.1177/00033197251365016 · Cited by 3
Current Challenges for the Diagnosis of HFpEF and Possible Simplification of the Diagnostic Approach
Bernardi, M., Golino, M., Spadafora, L., Sarto, G., Forte, M., Simeone, B., Rocco, E., Valenti, V., Schiavon, S., Esposito, A., et al. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001755 · Cited by 3
Valvular heart failure: evolving pharmacological approaches
Docherty, K. F., Otto, C. M., & McMurray, J. J. V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1079 · Cited by 3
Self-citationConsensus Statement on Optimisation of Patient Care After Hospitalisation for Acute Heart Failure
Sindone, A. P., Amerena, J. V., Pasquale, C. G. D., Chan, A., Gan, G. C. H., RAO, S. D., Burdeniuk, C., Shah, A. M., & Atherton, J. J. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.019 · Cited by 4
Qi, W., & Longfei, P. A. N. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1706383 · Cited by 3
Ismail, A., Erne, G. K., Vasbinder, A. L., Hutten, C. G., Ghazzal, B., Pizzo, I., Diaz, K. M., Catalan, T., Farhat, T., Knott, B., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.018 · Cited by 3
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 3
Defining a Path Toward Improved Heart Failure Care
Desai, N. R. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89418 · Cited by 3
Li, L., Dong, Y.-H., Bai, Y. S., Tang, Z., Deng, Y.-M., Wu, Z., & Li, W. (2023) · Endocrine · doi:10.1007/s12020-023-03618-x · Cited by 3
Maged, R., Sinha, M., Koneru, H. M., Sarwar, H., Bandi, V. V., Tarar, P., & Halawa, N. (2024) · Cureus · doi:10.7759/cureus.69623 · Cited by 3
Lundeberg, J. E., Wuopio, J., Mente, A., Måneheim, A., Okrajni, M., Healey, J. S., Sundström, J., Ärnlöv, J., Engström, G., & Johnson, L. (2025) · Heart · doi:10.1136/heartjnl-2024-324391 · Cited by 3
Zhang, X., Zhang, Y., Wang, J., & Tang, Z. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105809 · Cited by 4
Alruwaili, W., Ahmad, S. M., Berzingi, S., Atti, L., Taha, A., Thangjui, S., Thyagaturu, H. S., & Balla, S. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.06.006 · Cited by 3
Miyake, R., Kubota, T., Ishikita, A., Nakashiro, S., Nagatomo, D., Oi, K., & Suematsu, N. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0085 · Cited by 3
Ketone Bodies in Acute Heart Failure: Fuel for Thought
Manla, Y., Kuan, W., Clark, A. L., Cleland, J. G. F., & Pellicori, P. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.11.002 · Cited by 3
Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)
Morbach, C., & Störk, S. (2023) · Herz · doi:10.1007/s00059-022-05156-0 · Cited by 3
Alnsasra, H., Tsaban, G., Solomon, A., Khalil, F. M., Aboalhasan, E., Weinstein, J. M., Azuri, J., Hammerman, A., & Arbel, R. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00578-5 · Cited by 4
Romero, A., Saldarriaga, C., Ramos, C. E., Quesada, D., Chazzin, G., Fernández, F. N. G., Pow-Chon-Long, F., Alarco, W., Hurtado, P. E., Magaña, J. A., et al. (2023) · Archivos de cardiología de México · doi:10.24875/acm.23000059 · Cited by 3
Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts
Sánchez-Muñoz, E., Requena-Ibáñez, J. A., & Badimón, J. J. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.01.011 · Cited by 3
Non-acute heart failure management in primary care
Roskvist, R. P., Eggleton, K. S., Arroll, B., & Stewart, R. (2024) · BMJ · doi:10.1136/bmj-2023-077057 · Cited by 3
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Acute Coronary Syndrome
Song, J., Liu, Y., Xu, Y., & Hao, P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00076 · Cited by 3
Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
Fang, Y., Chen, L., Sun, S., & Ran, X. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11070198 · Cited by 3
Management of Patients With Chronic Coronary Disease
German, C. A., Davis, A. M., & Polonsky, T. S. (2024) · JAMA · doi:10.1001/jama.2024.9813 · Cited by 3
Forsyth, F., Deaton, C., Kalra, P. R., Green, M., Harrison, M., Tavares, S., Dirksen, A., Kuhn, I. L., Farquharson, B., & Austin, R. C. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae119 · Cited by 3
Addo, B., Agyeman, W. Y., Ibrahim, S., & Berchie, P. O. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00669-x · Cited by 3
Kim, S.-E., Lee, S., Oh, J., Lee, C. J., Hwang, S. H., Kang, W. J., & Kang, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-74191-0 · Cited by 3
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 3
Pharmacological management of heart failure: a patient-centred approach
Fibbi, G., Sato, R., Vatic, M., Genreith, F. P., & von Haehling, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418414 · Cited by 5
SGLT 2 Inhibitors: Mechanisms, Clinical Applications, and Future Directions
Çakmak, A. (2024) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.615 · Cited by 3
Muszyński, P., Cieślińska, M., Dziemidowicz, M., Bonda-Ostaszewska, E., Hirnle, T., & Bonda, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041664 · Cited by 3
Heart failure with preserved ejection fraction and atrial fibrillation
Lenormand, T., Bisson, A., & Fauchier, L. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09602-8 · Cited by 3
Complexities in Geriatric Cardiology: Clinical Dilemmas and Gaps in Evidence
Theodorakis, N., Hitas, C., Vamvakou, G. D., Kalantzi, S., Spyridaki, A., Kollia, Z., Feretzakis, G., & Nikolaou, M. (2025) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2025.01.004 · Cited by 4
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Izumida, T., & Kinugawa, K. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0004 · Cited by 3
Chen, X., Wang, L., Li, H., Huang, W., Huang, S., Zhao, L., & Guo, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1067806 · Cited by 3
Dapagliflozin in Heart Failure with Preserved Ejection Fraction
Gabrielli, D., Oliva, F. G., & Zuccalà, G. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2213974 · Cited by 3
Iguchi, M., Wada, H., Martínez, F. A., & Hasegawa, K. (2023) · European Cardiology Review · doi:10.15420/ecr.2022.62 · Cited by 3
Madaudo, C., Bromage, D. I., & Cannata, A. N. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2490403 · Cited by 4
2023 Updated European Society of Cardiology guidelines on heart failure
Rakisheva, A., & Kuanyshbekova, R. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5841 · Cited by 2
Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors
Demirkiran, C., Demiryürek, Ş., & Demiryürek, A. T. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575325210240805092741 · Cited by 3
Czulada, E., Smith, J., Kolm, P., Deb, B., Dolman, S. F., Alexander, N., Braun, R. A., Kabadi, R. A., Weintraub, W. S., Strouse, D., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.09.033 · Cited by 2
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 2
Li, Z., Zhu, S., Tang, W., Zhang, H., Le, W., Luo, S., Zhou, C., Wang, Y., Xu, S., Hu, W., et al. (2024) · Lupus · doi:10.1177/09612033241308105 · Cited by 2
Lo, K. B., Iskarous, K., & Sankaranarayanan, R. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.002 · Cited by 2
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Singh, A. K., Singh, A., & Singh, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464905 · Cited by 3
Arutyunov, G. P., Кононов, С. К., Novitsky, N. I., Багликов, А. Н., Shchendrygina, A., Андреевна, К. Е., Eruslanova, K. A., Сафроненко, В. А., Kopeva, K. V., & Soloveva, A. E. (2025) · Kardiologiia · doi:10.18087/cardio.2025.3.n2890 · Cited by 2
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
Su, A. Y., Csere, M. M., Shan, R. M., Pasupuleti, V., Valenzuela-Rodríguez, G., & Hernández, A. V. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112219 · Cited by 3
Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients
Yarar, M., Arı, H., Arı, S., Tütüncü, A., Melek, M., & Bozat, T. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2527189 · Cited by 2
Hamze, J., Harris, D. D., Stone, C. R., Muir, K. C., Broadwin, M., Kanuparthy, M., Abid, R., & Sellke, F. W. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177975 · Cited by 2
Lin, B.-H., Huang, H., Lin, H.-A., & Lin, S. (2025) · International Journal of Stroke · doi:10.1177/17474930251364060 · Cited by 2
Management von Risikofaktoren und Begleiterkrankungen bei Vorhofflimmern
Gunawardene, M., & Schmidt, B. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2516-8410 · Cited by 2
Natrium-Glukose-Co-Transporter-2 (SGLT-2)-Hemmer in der perioperativen Medizin
Nienhaus, J., Tenge, T., Riesemann, S., Kindgen‐Milles, D., Buse, G. L., M’Pembele, R., & Roth, S. (2025) · Die Anaesthesiologie · doi:10.1007/s00101-025-01580-z · Cited by 2
Association of SGLT2 inhibition with psychiatric disorders: A Mendelian randomization study
Liu, L., Li, C., Li, S., Zhan, J., & Liu, Y. (2025) · Open Medicine · doi:10.1515/med-2025-1278 · Cited by 2
Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 2
Shen, L., Shen, L., Cheang, I., Yao, W., Zhu, X., Zhang, Y., Yang, Y., Li, Q., Zhang, H., Petrie, M. C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf017 · Cited by 3
Self-citationWu, J., Tseng, K.-J., Kao, C., Hung, K., Yu, T., & Lin, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1652863 · Cited by 2
Odutayo, A., Bhatt, D. L., Sridhar, V. S., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Lópes, R. D., Scirica, B. M., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013054 · Cited by 3
Spagnolin, M., Fazzini, L., Giaccherini, C., D’Elia, E., Chiesa, E., Zucchi, A., Gavazzi, A., Senni, M., & Gori, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag037 · Cited by 2
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
Kok, T. F., van Essen, B. J., Weerts, J., Yang, Y., Achten, A., Gansevoort, R. T., Bakker, S. J. L., van Empel, V. P. M., Damman, K., Boersma, E. H., et al. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.08.022 · Cited by 2
Tanaka, A. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0129 · Cited by 4
Wilcox, J. E., Lund, L. H., Cox, Z. L., Ho, J. E., Lam, C. S. P., Sharma, K., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.024 · Cited by 2
Self-citationMallardo, M., Filardi, P. P., Micheletto, C., Montano, N., Spampinato, A., Volterrani, M., Zito, G., Agosti, S., Avogadri, E., Basile, C., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106881 · Cited by 2
Chu, Y., Huang, K.-H., & Tseng, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094101 · Cited by 2
Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
The “Cairo Accord”- towards the eradication of RHD: revisited (2026)
Kotit, S., & Yacoub, M. H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1799972 · Cited by 2
Basta, D., Refaei, A. H. A., Msinjili, L., Frishman, W. H., & Lebovics, E. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001298 · Cited by 3
Ghnaimat, A. A., Ahmed, N. A. T., Al-Azzawi, O. M., Ibrahim, E. A., Rayyan, R., Alkloub, S., Joufi, E. A., Breish, E. E., Shaik, S., Al-Kadhimi, N., et al. (2026) · International Journal of Hepatology · doi:10.1155/ijh/7257876 · Cited by 2
Chai, X.-J., Wei, G., Chen, W., Min, D.-Y., Wang, Y., & Guan, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1801502 · Cited by 2
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 2
Kajiwara‐Morita, A., Kugimoto, S., Oniki, K., Yoshida, A., Kurinami, N., Suzuki, T., MIYAMOTO, F., Hieshima, K., Sugiyama, S., Kajiwara, K., et al. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261462669 · Cited by 2
Kazé, A. D., Juraschek, S. P., Cohen, J. B., Zawaneh, M. S., Ndumele, C. E., Ballantyne, C. M., Berry, J. D., & Echouffo-Tcheugui, J. B. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103096 · Cited by 2
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Aletras, G., Stylianou, K., Marketou, M. E., Stratinaki, M., Papayiannaki, A., Pantazis, Y., Hamilos, M., & Foukarakis, E. G. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13090423 · Cited by 2
SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis
Onoue, T., & Kataoka, M. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01220-z · Cited by 2
Patoulias, D., Kassimis, G., & Fragakis, N. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106619 · Cited by 2
Sodium-Glukose-Transporter 2-Hemmer bei Herzinsuffizienz mit erhaltener Auswurffraktion
Böhm, M., & Bauersachs, J. K. (2023) · Die Kardiologie · doi:10.1007/s12181-023-00598-0 · Cited by 2
The growing clinical effect of SGLT2 inhibitors
Prato, S. D. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00065-7 · Cited by 2
Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?
Sawami, K., Tanaka, A., & Node, K. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad084 · Cited by 2
Koshino, A., Neuen, B. L., Oshima, M., Toyama, T., Hara, A., Arnott, C. G., Neal, B. C., Jardine, M., Badve, S. V., Mahaffey, K. W., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.024 · Cited by 2
In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Debnath, A., Sharma, S., Mazumder, R., Mazumder, A., Singh, R. K., Kumar, A., Dua, A., Singhal, P., Kumar, A., & Singh, G. (2023) · Current Drug Discovery Technologies · doi:10.2174/0115701638267615231123160650 · Cited by 2
Rethinking the Impact and Management of Diabetes in Heart Failure Patients
Schütt, K. S. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00633-x · Cited by 2
Role of Sodium-Glucose Co-Transporter-2 Inhibitor During Anthracycline Use: An Updated Review
Basham, H. A., Keswani, S., Kumar, A., Rahol, S. K. A., Surkasha, F., Kumari, A., & Malik, J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000638 · Cited by 2
Inhibición dual del SGLT1 y SGLT2: algo más que su suma
Sánchez-Muñoz, E., Requena-Ibáñez, J. A., & Badimón, J. J. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.01.005 · Cited by 2
Sabanci, R., Saeed, M., Bandi, A. R., Das, K., & Wilcox, M. (2024) · Cureus · doi:10.7759/cureus.55068 · Cited by 2
Use of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils
Peter, P. R., & Inzucchi, S. E. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.022 · Cited by 2
Self-citationНиколаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
Full decongestion in acute heart failure therapy
Buttar, C., Alai, H. R., Matanes, F. N., Cassidy, M. M., Stencel, J. D., & Jemtel, T. H. L. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.06.002 · Cited by 2
Molecular Mechanisms of the Failing Heart: A Fatal Regression?
Katoh, M., Komuro, J., Inoue, S., Nakayama, Y., & Komuro, I. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2024.07 · Cited by 2
Advances in heart failure management
Zamorano, J. L., & Leal, A. G. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.06.001 · Cited by 2
Akunne, O. Z., & Anulugwo, O. E. (2024) · American Journal of Pharmacotherapy and Pharmaceutical Sciences · doi:10.25259/ajpps_2024_013 · Cited by 3
Diuretic Combination Therapy in Acute Heart Failure: An Updated Review
Villaschi, A., Pellegrino, M., Condorelli, G., & Chiarito, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128316596240625110337 · Cited by 2
Ghukasyan, H., Navalha, D. D. P., Romero, I. P., Wolwacz, M. V. P., Ghahramanyan, A., Ngan, C. W. T., de Melo, M. H. S. T., Dagostin, C. S., & Quirós, L. G.-L. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.06.004 · Cited by 2
Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure
Kaźmierski, W., Jurek, J., Lis, P., Lis, A. E., Ziobro, A., Ziomek, M., Camlet, K., & Kocur, K. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.240 · Cited by 2
The past, present, and future of mechanical circulatory and respiratory support
Gregory, S. D., Stephens, A. F., Heinsar, S., Arens, J., & Fraser, J. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22148-4.00037-x · Cited by 2
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
